Message #15 From:
NewsBot Date: January 16, 2007 06:26:00 AM
GLIF News Grant Life Sciences Signs MOU (Memorandum of Understanding) with Taiwan's Leading Clinical Reference Laboratory
LOS ANGELES--(BUSINESS WIRE)--Grant Life Sciences (‘Grant’)
Inc. (OTC BB: GLIF) announced today that it has signed an MOU
(Memorandum of Understanding) with Union Clinical Laboratory (UCL) of
Taiwan, the leading laboratory serving the clinical diagnostics market
in Taiwan—which represents a major milestone
for progressing the Company’s strategic plan
to build a strong presence in global markets.
“We are very pleased to collaborate with UCL—the
largest clinical reference laboratory that provides more than 30 percent
of referral laboratory services in Taiwan—to
validate our technologies. Grant has been focusing on the development of
HPV (Human Papillomavirus) diagnostics, and we expect that UCL will play
a critical role in validating our assays in collaboration with
UCL-affiliated medical institutes that are designing and managing
clinical trials with our products,” said
Hun-Chi Lin, Ph.D., Grant’s President and
Chief Scientist.
“In addition, our diagnostics products will
be manufactured in Taiwan, which offers lower cost and high quality for
making them available and affordable to the global medical specialists
dealing with cervical cancers closely associated with HPV,”
added Dr. Lin. “There are over 300,000 women
who die from cervical cancer each year worldwide, and 90,000 in the
Greater China area. Our recently appointed Greater China Regional
Director, Mr. Kim Liao, will now be able to oversee this product
development process with support from the highest-quality partners in
this important market.”
(“Greater China”
refers collectively to both the territories administered by the People’s
Republic of China—mainland China, Hong Kong
and Macau—as well as territories administered
by the Republic of China—Taiwan, and some
neighboring islands.)
About Union Clinical Laboratory (UCL)
Founded in 1973, privately held UCL is the largest commercial clinical
reference laboratories in Taiwan, serving hospitals, clinics, major
global pharmaceutical companies, CROs and biomedical research
institutions domestically and internationally. Accredited by TAF
(Taiwanese Accreditation Foundation), UCL is a GLP-compliant laboratory
and an active participant of CAP (College of American Pathologists)
Survey programs.
About Grant Life Sciences Inc.
Grant Life Sciences engages in research, development, marketing, and
sale of diagnostic kits for the screening, monitoring, and diagnosis of
diseases with emphasis on women’s health,
infectious diseases, and cancers.
Forward-Looking Safe Harbor Statement
With the exception of historical information, the matters discussed in
this press release are "forward-looking statements" that involve a
number of risks and uncertainties. The actual future results of Grant
Life Sciences could differ significantly from those statements. Factors
that could cause actual results to differ materially include risks and
uncertainties such as the inability to finance the company's operations
or expansion, inability to hire and retain qualified personnel, changes
in the general economic climate, including rising interest rates and
unanticipated events such as terrorist activities, results of clinical
trials, and market acceptance of the Company's products. In some cases,
"forward-looking statements" can be identified by terminology such as
"may," "will," "should," "expect," "plan," "anticipate," "believe,"
"estimate," "predict," "potential" or "continue," or other comparable
terminology. Although Grant Life Sciences believes that the expectations
reflected in the "forward-looking" statements are reasonable, such
statements should not be regarded as a representation by the Company, or
any other person, that such "forward-looking statements" will be
achieved. Grant Life Sciences undertakes no duty to update any of the
"forward-looking statements," whether as a result of new information,
future events or otherwise. In light of the foregoing, readers are
cautioned not to place undue reliance on such "forward-looking
statements." For further risk factors associated with our Company,
review our SEC filings.
